Usage: hover your mouse-pointer anywhere on the image above to see an enlarged portion of the image. You can also just click the image to see the original-sized version.
|Liquid Biopsy. Tissue biopsies are invasive and non-feasible for longitudinal monitoring of patients; moreover, they do not capture the heterogeneity of the tissue or a disease of interest. Liquid biopsies are non-invasive and enable real time snapshot of the tissue homeostasis or alterations by detection of relevant biomarkers in the bloodstream. Tissue or disease specific exosomes and extracellular vesicles (EVs) can be isolated and analyzed from routine blood or urine samples featuring the ideal platform for biomarker discovery and clinical diagnostic development. The major challenge and opportunity in using EVs based liquid biopsy lies in the tremendous complexity of biofluid samples, heterogeneity of exosomes and extracellular vesicles and the low abundance of specific tissue or disease markers. HansaBioMed Life Sciences provides a range of pre-analytical solutions, empowered by Exosomics s.p.a, to isolate either overall EVs or selectively enrich for specific subpopulations (i.e. tumor derived-EVs) from biofluids with high yield and purity, and further extract their DNA and RNA content. Our technologies are efficient in both biomarker discovery and confirmation studies, and comply with clinical grade analytical platforms. In clinical settings, our solutions enable ultrasensitive detection of tumor associated mutations and RNA molecules, enabling next generation of tumor screening, monitoring, staging and monitoring tests. Preanalytical assay: enrichment of tumor derived genomic DNA from human biofluids. SeleCTEV™ DNA Enrichment Kit allows the selective purification of circulating free DNA (cfDNA) and tumor-derived extracellular vesicles (EVs) DNA from plasma. The isolation is based on Exosomics’ proprietary peptide affinity method.
|HansaBioMed Life Sciences
|+ 4 °C
|+ 4 °C
|Go to webpage